Evidence map›Paper›PMID 40676646›Full record

ArticleArthritis research & therapy2025

Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis.

Marina G Birck, Jessica Boivin, Laura Yan, Nathalie Carrier, Cristiano S Moura, Walter P Maksymowych, Gilles Boire, Denis Choquette, Luck Lukusa, Michael Mallinson and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marina G Birck *Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Jessica Boivin *Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Laura YanMcGill University, Montreal, QC, Canada.
Nathalie CarrierCentre integré universitaire de santé et de services sociaux de l'Estrie- Centre hospitalier de Sherbrooke (CIUSSS de l'Estrie-CHUS), Sherbrooke, QC, Canada.
Cristiano S MouraResearch Institute of the McGill University Health Centre, Montreal, QC, Canada.
Walter P MaksymowychUniversity of Alberta, Edmonton, AB, Canada.
Gilles BoireCentre integré universitaire de santé et de services sociaux de l'Estrie- Centre hospitalier de Sherbrooke (CIUSSS de l'Estrie-CHUS), Sherbrooke, QC, Canada.
Denis ChoquetteInstitut de Rhumatologie de Montréal, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Luck LukusaResearch Institute of the McGill University Health Centre, Montreal, QC, Canada.
Michael MallinsonCanadian Spondylitis Association, and Axial Spondyloarthritis International Federation, Toronto, Canada.
Linda WilhelmCanadian Arthritis Patient Alliance, Toronto, ON, Canada.
Autumn NevilleResearch Institute of the McGill University Health Centre, Montreal, QC, Canada.
Sasha BernatskyResearch Institute of the McGill University Health Centre, Montreal, QC, Canada. sasha.bernatsky@mcgill.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O).

methodsWe studied etanercept-naive participants with RA from four Canadian prospective cohorts who initiated ETA-B or ETA-O (Jan/2015-May/2022). Disease remission was determined using disease activity scales. Sustained remission was defined as at least two consecutive visits in remission within the first 12 months of follow-up. Multivariate Cox regression was used to compare the probability of achieving remission between ETA-B and ETA-O, and multivariate logistic regression was used to assess sustained remission.

resultsWe studied 150 participants with RA (ETA-B: 65.3%). Among 125 participants not in remission at baseline, the median time to first remission was 8.7 months (95% confidence intervals [CI] 5.2-12.1) in the ETA-B group and 14.5 months (95% CI 4.7-18.6) in the ETA-O group. Time to first remission was similar between the groups (log-rank test: P-value = 0.51). Multivariate Cox regression showed no clear difference in first remission between ETA-B and ETA-O (adjusted hazard ratio 1.52, 95% CI 0.68-3.39). Among 125 participants with at least 12 months of follow-up, the prevalence of sustained remission was 19.5% for ETA-B and 21.0% for ETA-O. In multivariate analysis, we did not detect a significant difference in sustained remission between ETA-B and ETA-O (adjusted odds ratio 1.14, 95% CI 0.29-4.87).

conclusionWe did not detect clear differences in first remission and sustained remission between participants with RA initiating ETA-B or ETA-O.

trial registrationNot applicable.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidBiosimilar PharmaceuticalsEtanerceptAdultAgedCanadaFemaleHumansMaleMiddle AgedProspective StudiesRemission InductionTreatment OutcomeAntirheumatic AgentsBiosimilar PharmaceuticalsEtanerceptBiosimilar pharmaceuticalsEtanerceptRemission inductionRheumatoid arthritis

Identifiers

PMID40676646
PMCPMC12273282

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.